Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

Официальное название

Efficacy and Safety of Cryopreserved Autologous Mobilized Peripheral Blood CD34+ HSPCs Transduced Ex Vivo With the EFS-ADA Lentiviral Vector in Patients With Severe Combined Immune Deficiency Due To Adenosine Deaminase Deficiency

Обзор

The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.

Подробное описание

The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA complementary DNA (cDNA) will be used to transduce autologous CD34+ cells from Granulocyte Colony Stimulating Factor (G-CSF)/Plerixafor mobilized Peripheral Blood (mPB) of these subjects. The subjects will receive pharmacokinetically-adjusted busulfan reduced intensity conditioning prior to re-infusion of their gene-modified cells. Overall survival at two years is the primary endpoint. During the follow-up phase, the investigators aim to determine whether the cells could engraft and produce mature cells that contain and express the corrected ADA gene in the absence of pegylated adenosine deaminase (PEG-ADA) enzyme replacement therapy (ERT), which will be withheld starting on Day +30 following transplant. Efficacy studies to evaluate the level of immune reconstitution, will be performed in the two years of the study. Patients will be asked to enroll into a long-term follow-up study to reach a total of 15 years follow-up after gene therapy.

Вмешательства

• Комбинированный продукт A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
  Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan

Первичные конечные точки

• Survival [Срок оценки: 24 months]

Вторичные конечные точки (9)

• Evaluate Safety from clinical adverse events. [Срок оценки: 24 months]
• Evaluate Safety from replication competent lentivirus by quantitative polymerase chain reaction (qPCR) assay. [Срок оценки: 24 months]
• Evaluate Safety from vector-related clonal expansion by non-restrictive Linear Amplification Polymerase Chain Reaction (nrLAM-PCR) [Срок оценки: 24 months]
• Record event free survival at 24 months [Срок оценки: 24 months]
• Determine incidence of Infection over two years after gene therapy [Срок оценки: 24 months]
• Neuro-developmental Outcomes by neurodevelopmental testing (subjects 5-7 yeas of age) [Срок оценки: 24 months]
• Neuro-developmental Outcomes by neurodevelopmental testing (subjects 1 year -42 month of age) [Срок оценки: 24 months]
• Neuro-developmental Outcomes by Brain Stem Evoked Response (BAER) testing [Срок оценки: 24 months]
• Cessation of immunoglobulin replacement therapy (IgRT). [Срок оценки: 24 months]

Критерии участия

Критерии включения

All subjects must fulfill the following criteria to be included in the study:

• Provision of written informed consent prior to any study related procedures. In this study consent must be provided by the parents/legal guardians and, where applicable according to local laws, a signed assent from the child,
• Subjects ≥30 days of age,
• With a diagnosis of ADA-SCID based on:

Evidence of ADA deficiency, defined as:

i. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal cells to levels consistent with ADA-SCID as determined by the reference laboratory, or ii. Identified mutations in ADA alleles consistent with a severe reduction in ADA activity,

Evidence of ADA-SCID based on either:

i. Family history of a first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, or ii. Evidence of severe immunologic deficiency in subjects prior to the institution of immune restorative therapy, based on

• Lymphopenia (absolute lymphocyte count (ALC) <400 cells/mL) OR absence or low number of T cells (absolute CD3+ count < 300 cells/mL), or
• Severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (either <10% of lower limit of normal controls for the diagnostic laboratory, or <10% of the response of the normal control of the day, or stimulation index <10), or
• Identification of SCID by neonatal screening revealing low T Cell Receptor Excision Circles (TREC) levels.
• Ineligible for matched family allogeneic bone marrow (BM) transplantation, defined as the absence of a medically eligible HLA-identical sibling or family donor, with normal immune function, who could serve as an allogeneic bone marrow donor.
• Females of child-bearing age will be required to provide a negative pregnancy test 30 days prior to Visit 2.
• Subjects and their parents/legal guardians must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period and willing to return to the clinic for the follow up evaluation as specified in the protocol.

Критерии исключения

Subjects will not be eligible for the study if any of the following criteria is fulfilled:

• Ineligible for autologous HSCT as per clinical site criteria
• Other conditions which in the opinion of the Principal Investigator and/or Co Investigators, contraindicate the mobilization of peripheral blood or the leukapheresis process, the administration of busulfan and the infusion of transduced cells, or which indicate an inability of the subject or subject's parent/legal guardian to comply with the protocol
• Hematologic abnormality, defined as:

• Anemia (Hb <8.0 g/dl).
• Neutropenia (ANC <500/mm3). Note: ANC <500 with absence of myelodysplastic syndrome on bone marrow aspirate and biopsy and normal marrow cytogenetics are acceptable for eligibility.
• Thrombocytopenia (platelet count <50,000/mm3, at any age).
• Prothrombin time or international normalized ratio (INR) and partial thromboplastin time (PTT) >2 x upper limit of normal (ULN) (subjects with a correctable deficiency controlled on medication will not be excluded).
• Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid (if available).
• Prior allogeneic HSCT with cytoreductive conditioning.
• Pulmonary abnormality, defined as:

• Resting O2 saturation by pulse oximetry <90% on room air.
• Chest X-ray indicating active or progressive pulmonary disease. Note: Chest X ray indicating residual signs of treated pneumonitis is acceptable for eligibility.
• Cardiac abnormality, defined as:

• Abnormal ECG indicating cardiac pathology.
• Uncorrected congenital cardiac malformation with clinical symptoms.
• Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension.
• Poor cardiac function as evidenced by left ventricular ejection fraction <40% on echocardiogram.
• Neurologic abnormality, defined as:

• Significant neurologic abnormality revealed by examination.
• Uncontrolled seizure disorder.
• Renal abnormality, defined as:

• Renal insufficiency: serum creatinine ≥1.2 mg/dl (106 µmol/L), or ≥3+ proteinuria.
• Abnormal serum sodium, potassium, calcium, magnesium or phosphate levels at >2 x ULN.
• Hepatic/gastrointestinal abnormality, defined as:

• Serum transaminases >5 x ULN.
• Serum bilirubin >2 x ULN.
• Serum glucose >1.5 x ULN.
• Oncologic disease, defined as:

• Evidence of active malignant disease other than dermatofibrosarcoma protuberans (DFSP).
• Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells (if anti-neoplastic therapy has been completed, a subject with a history of DFSP can be included).
• Evidence of DFSP expected to be life limiting within the 5 years following the infusion of genetically corrected cells.
• Known sensitivity to Busulfan.
• Confirmation of an infectious disease by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) positive at time of assessment for the following:

• HIV-1,
• Hepatitis B,
• Parvovirus B19.
• The subject is pregnant or has a major congenital anomaly.
• Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
• The subject has previously received another form of gene therapy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 1 центр

• University of California, Los Angeles (UCLA) — Los Angeles

Публикации

• Carbonaro DA, Zhang L, Jin X, Montiel-Equihua C, Geiger S, Carmo M, Cooper A, Fairbanks L, Kaufman ML, Sebire NJ, Hollis RP, Blundell MP, Senadheera S, Fu PY, Sahaghian A, Chan RY, Wang X, Cornetta K, Thrasher AJ, Kohn DB, Gaspar HB. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. PMID 24256635
• Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, Carbonaro-Sarracino DA, Soni K, Terrazas D, Snell K, Ikeda A, Leon-Rico D, Moore TB, Buckland KF, Shah AJ, Gilmour KC, De Oliveira S, Rivat C, Crooks GM, Izotova N, Tse J, Adams S, Shupien S, Ricketts H, Davila A, Uzowuru C, Icreverzi A, Barman P, Campo Fernandez B, Hollis RP, Coronel M, Yu A, Chun KM, Casas CE, Zhang R, Arduini S, PMID 33974366

Идентификаторы

NCT: NCT05432310 · UCLA IRB#21-001814

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗